Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sugi, T.
Right arrow Articles by McIntyre, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugi, T.
Right arrow Articles by McIntyre, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 18, No. 7, 1553-1554, July 2003
© 2003 European Society of Human Reproduction and Embryology

Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population

Toshitaka Sugi1,3 and John A. McIntyre2

1 Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan and 2 HLA Vascular Biology Laboratory, St. Francis Hospital and Health Centers Indianapolis, IN, USA

3 To whom correspondence should be addressed. e-mail: sugi@is.icc.u-tokai.ac.jp

The first 10% of the full text of this article appears below.

Dear Sir,

We read the recent article by Franklin and Kutteh (2002Go), concerning the pregnancy outcomes of recurrent pregnancy loss (RPL) patients who had normal obstetrical evaluations with the exception of positive antiphospholipid antibodies (aPL) findings. In their report distinctions were made between two groups of aPL positive RPL patients with reference to their aPL specificities. Group 1 patients had ‘the common’ aPL, anticardiolipin (aCL), or antiphosphatidylserine antibodies (aPS) and/or a lupus anticoagulant (LAC). For comparisons, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?